Breaking cost barriers: The EnzeneX® revolution in Animal Health Manufacturing

Cost pressure in Animal Health isn’t going away — and manufacturing innovation is becoming the key lever for sustainable biologics production.

In this on-demand session, Russell Miller, VP Global Sales & Marketing at Enzene Biosciences, discusses how EnzeneX®, a fully-connected continuous manufacturing platform, is helping redefine veterinary monoclonal antibody (vet mAb) production.

What you’ll learn in this session:

• Predictable scale-up from 200 L → 500 L
• Higher productivity and effective titers
• Meaningful cost-of-goods (COGS) reduction compared to traditional fed-batch processes
• Process controls designed to protect critical quality attributes (CQAs)

If scalable, cost-efficient animal health manufacturing is part of your roadmap, this session offers practical insights into next-generation biologics production.